PubRank

B I Carr

Author PubWeight™ 71.89‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 The prediction of risk of recurrence and time to recurrence of hepatocellular carcinoma after orthotopic liver transplantation: a pilot study. Hepatology 1997 2.57
2 Inhibition of DNA synthesis in rat hepatocytes by platelet-derived type beta transforming growth factor. Cancer Res 1986 1.97
3 Hepatic parenchymal perfusion defects detected with CTAP: imaging-pathologic correlation. Radiology 1992 1.70
4 Growth inhibition by transforming growth factor beta (TGF-beta) type I is restored in TGF-beta-resistant hepatoma cells after expression of TGF-beta receptor type II cDNA. Proc Natl Acad Sci U S A 1993 1.64
5 Modulation of insulin-like growth factor-II/mannose 6-phosphate receptors and transforming growth factor-beta 1 during liver regeneration. J Biol Chem 1991 1.31
6 Utilization of hepatocyte-specific antibody in the immunocytochemical evaluation of liver tumors. Mod Pathol 1997 1.22
7 Treatment before liver transplantation for HCC. Ann Surg Oncol 2008 1.22
8 Detection of liver cells in peripheral blood of patients with advanced-stage hepatocellular carcinoma. Hepatology 1995 1.21
9 Percutaneous biopsy of portal vein thrombus: a new staging technique for hepatocellular carcinoma. AJR Am J Roentgenol 1993 1.20
10 An assay for micrometastatic hepatocellular carcinoma. Gastroenterology 1994 1.16
11 Prognostic significance of arterial phase CT for prediction of response to transcatheter arterial chemoembolization in unresectable hepatocellular carcinoma: a retrospective analysis. AJR Am J Roentgenol 2000 1.10
12 Clinically meaningful changes in health-related quality of life in patients diagnosed with hepatobiliary carcinoma. Ann Oncol 2005 1.08
13 Effects of rapamycin on cultured hepatocyte proliferation and gene expression. Hepatology 1992 1.06
14 Growth inhibition of hepatoma cells induced by vitamin K and its analogs. J Biol Chem 1995 1.03
15 In situ hybridization of albumin mRNA in normal liver and liver tumors: identification of hepatocellular origin. Virchows Arch B Cell Pathol Incl Mol Pathol 1993 0.96
16 The inhibitory effect of interleukin 1beta on rat hepatocyte DNA synthesis is mediated by nitric oxide. Hepatology 1998 0.94
17 Hepatocyte proliferation and gene expression induced by triiodothyronine in vivo and in vitro. Hepatology 1994 0.94
18 Percutaneous fine-needle aspiration of portal vein thrombi as a staging technique for hepatocellular carcinoma. Cytologic findings of 46 patients. Cancer 1995 0.93
19 The tumorigenicity of 5-azacytidine in the male Fischer rat. Carcinogenesis 1984 0.93
20 Cell surface-mediated cytotoxicity of polymer-bound Adriamycin against drug-resistant hepatocytes. Cancer Res 1983 0.93
21 DNA synthesis in rat hepatocytes: inhibition by a platelet factor and stimulation by an endogenous factor. J Cell Physiol 1985 0.91
22 Multiple genetic alterations, 4q28, a new suppressor region, and potential gender differences in human hepatocellular carcinoma. Hepatology 1999 0.90
23 Radiation therapy for primary carcinoma of the extrahepatic biliary system. An analysis of 63 cases. Cancer 1991 0.89
24 Recurrent hepatocellular carcinoma after liver transplantation: spectrum of CT findings and recurrence patterns. Radiology 1996 0.89
25 Causes of death in patients with unresectable hepatocellular carcinoma. Dig Dis Sci 2007 0.88
26 Induction of heat shock gene expression without heat shock by hepatocarcinogens and during hepatic regeneration in rat liver. Cancer Res 1986 0.88
27 Cdc25 inhibition and cell cycle arrest by a synthetic thioalkyl vitamin K analogue. Cancer Res 2000 0.87
28 Growth control and gene expression in a new hepatocellular carcinoma cell line, Hep40: inhibitory actions of vitamin K. J Cell Physiol 1995 0.87
29 Renal carcinoma manifesting as breast mass. Urology 1983 0.87
30 The growth inhibitory effects of vitamins K and their actions on gene expression. Hepatology 1995 0.86
31 Percutaneous ultrasound-guided needle biopsy of hepatic mass lesions using a cytohistologic approach. Comparison of two needle types. Am J Clin Pathol 1995 0.86
32 The variable transformation in metastases from testicular germ cell tumors: the need for selective biopsy. J Urol 1981 0.85
33 Differentially expressed genes in TGF-beta 1 sensitive and resistant human hepatoma cells. Cancer Lett 1995 0.85
34 Changes in TGF-beta receptors of rat hepatocytes during primary culture and liver regeneration: increased expression of TGF-beta receptors associated with increased sensitivity to TGF-beta-mediated growth inhibition. J Cell Physiol 1998 0.84
35 Prognostic models in hepatocellular carcinoma (HCC) and statistical methodologies behind them. Curr Pharm Des 2007 0.84
36 Stimulation of hepatocyte DNA synthesis by neurotensin. J Cell Physiol 1994 0.83
37 Antisense oligonucleotides: inhibition of liver cell proliferation and in vivo disposition. Transplant Proc 1992 0.83
38 Radiotherapy and multimodality management of cholangiocarcinoma. Int J Radiat Oncol Biol Phys 1999 0.83
39 Concomitant and isolated expression of TGF-alpha and EGF-R in human hepatoma cells supports the hypothesis of autocrine, paracrine, and endocrine growth of human hepatoma. J Surg Oncol 1995 0.83
40 A phase II study of raltitrexed ('Tomudex') in patients with hepatocellular carcinoma. Ann Oncol 1997 0.83
41 The use of granulocyte-macrophage colony-stimulating factor to enhance hematologic parameters of patients with cirrhosis and hypersplenism. J Hepatol 1994 0.82
42 Fetal hemoglobin gene activation in a phase II study of 5,6-dihydro-5-azacytidine for bronchogenic carcinoma. Cancer Res 1987 0.82
43 Inhibition of hepatoma cell growth in vitro by arylating and non-arylating K vitamin analogs. Significance of protein tyrosine phosphatase inhibition. J Biol Chem 1999 0.82
44 Cell growth inhibition by a novel vitamin K is associated with induction of protein tyrosine phosphorylation. J Biol Chem 1998 0.82
45 Transforming growth factor alpha (TGFalpha) in hepatocellular carcinomas and adjacent hepatic parenchyma. Hum Pathol 1998 0.81
46 Intrahepatic chemoembolization in unresectable pediatric liver malignancies. Pediatr Radiol 2000 0.81
47 ERCP and stent therapy for progressive jaundice in hepatocellular carcinoma: which patients benefit, which patients don't? Dig Dis Sci 1999 0.81
48 Neurotensin-amplification of DNA synthesis stimulated by EGF or TGF alpha in primary cultures of adult rat hepatocytes. Cell Struct Funct 1993 0.80
49 Chemical carcinogens and inhibitors of carcinogenesis in the human diet. Cancer 1985 0.80
50 High-dose continuous infusion folinic acid and bolus 5-fluorouracil in patients with advanced colorectal cancer: a phase II study. J Clin Oncol 1986 0.80
51 Cdc25A protein phosphatase: a therapeutic target for liver cancer therapies. Anticancer Agents Med Chem 2008 0.80
52 Mechanism of novel vitamin K analog induced growth inhibition in human hepatoma cell line. J Hepatol 2001 0.79
53 Mutation at codon 249 of p53 gene in a human hepatoblastoma. Hepatology 1993 0.79
54 Chronic treatment with phenobarbital decreases the expression of rat liver EGF and insulin receptors. Biochem Biophys Res Commun 1986 0.79
55 Spatial analysis of key signaling proteins by high-content solid-phase cytometry in Hep3B cells treated with an inhibitor of Cdc25 dual-specificity phosphatases. J Biol Chem 2001 0.79
56 Involvement of Cdc25A phosphatase in Hep3B hepatoma cell growth inhibition induced by novel K vitamin analogs. Cancer Res 2001 0.79
57 A comparison of the antiemetic efficacy of prochlorperazine and metoclopramide for the treatment of cisplatin-induced emesis: a prospective, randomized, double-blind study. J Clin Oncol 1985 0.79
58 Small-for-size liver transplanted into larger recipient: a model of hepatic regeneration. Hepatology 1994 0.79
59 Expression of the Hoxa-13 gene correlates to hepatitis B and C virus associated HCC. Biochem Biophys Res Commun 2001 0.79
60 Expression of rat microsomal epoxide hydrolase gene during liver chemical carcinogenesis. Cancer Res 1990 0.79
61 A liver colony assay for a new hepatocyte phenotype as a step toward purifying new cellular phenotypes that arise during hepatocarcinogenesis. Ann N Y Acad Sci 1980 0.79
62 Carcinogen-induced drug resistance in rat hepatocytes. Cancer Res 1981 0.78
63 Tumor cell growth inhibition and extracellular signal-regulated kinase (ERK) phosphorylation by novel K vitamins. J Mol Biol 2001 0.78
64 Effects of diethylnitrosamine on hepatic receptor binding and autophosphorylation of epidermal growth factor and insulin in rats. J Natl Cancer Inst 1986 0.78
65 The role of psychosocial factors in the progression of hepatocellular carcinoma. Med Hypotheses 2004 0.78
66 Inhibition of spermidine synthase gene expression by transforming growth factor-beta 1 in hepatoma cells. Biochem J 1997 0.78
67 Critical role of extracellular signal-regulated kinase (ERK) phosphorylation in novel vitamin K analog-induced cell death. Jpn J Cancer Res 2000 0.78
68 Growth inhibition and protein tyrosine phosphorylation in MCF 7 breast cancer cells by a novel K vitamin. J Cell Physiol 2000 0.78
69 Identification of a human hepatocellular carcinoma-associated tumor suppressor gene by differential display polymerase chain reaction. Life Sci 1995 0.77
70 Transforming growth factor beta 1 selectively increases gene expression of the serine/threonine kinase receptor 1 (SKR1) in human hepatoma cell lines. Cell Struct Funct 1994 0.77
71 Endothelin-1 expression by human hepatocellular carcinoma. Biochem Biophys Res Commun 1995 0.77
72 Binding of growth hormone to rat liver during experimental chemical hepatocarcinogenesis. Endocrinology 1986 0.77
73 Integration of hepatitis B virus and alteration of the 1p36 region found in cancerous tissue of primary hepatocellular carcinoma with viral replication evidenced only in noncancerous, cirrhotic tissue. Hepatology 1995 0.77
74 Cancer in Bangladesh: a model for some problems and proposed solutions in the Third World. Cancer Detect Prev 1986 0.77
75 Differential display and cloning of messenger RNAs from the late phase of rat liver regeneration. Biochem Biophys Res Commun 1995 0.77
76 Resistance to the cytocidal effects of adriamycin is an early phenotypic change induced during hepatocarcinogenesis. Br J Cancer 1981 0.76
77 Binding of epidermal growth factor and insulin and the autophosphorylation of their receptors in experimental primary hepatocellular carcinomas. Cancer Res 1986 0.76
78 Characterization of a human hepatoma cell line with acquired resistance to growth inhibition by transforming growth factor beta 1 (TGF-beta 1). In Vitro Cell Dev Biol Anim 1995 0.76
79 Cell physiology of antisense TGF-beta oligomers in hepatoma cells. Ann N Y Acad Sci 1992 0.75
80 Experimental chemical hepatocarcinogenesis: early membrane changes of significance for drug resistance. J Cell Physiol Suppl 1986 0.75
81 Effect of the cancer recognition, immunedefense suppression, and serine protease protection peptide on DNA synthesis in rat hepatocytes and human lymphocytes. Cancer Detect Prev 1995 0.75
82 Does advanced cirrhosis with portosystemic shunting affect the value of CT arterial portography in the evaluation of the liver? AJR Am J Roentgenol 1995 0.75
83 Continuous infusion prochlorperazine: pharmacokinetics, antiemetic efficacy, and feasibility of high-dose therapy. Cancer Chemother Pharmacol 2001 0.75
84 Differential interaction of normal and preneoplastic hamster bronchi with adriamycin. Cancer Res 1986 0.75
85 Combination chemotherapy with cytosine arabinoside (Ara-C) and cis-diamminedichloroplatinum (CDDP) for squamous cancers of the upper aerodigestive tract. Am J Clin Oncol 1989 0.75
86 Glutamic acid potentiates hepatocyte response to mitogens in primary culture. J Cell Physiol 1994 0.75
87 Possible association between HLA-AW24 and metastatic testicular germ-cell tumours. Lancet 1979 0.75
88 Herniated lumbar disc disease in patients with malignancy. J Clin Oncol 1987 0.75
89 Effects of the hepatocarcinogen 2-acetylaminofluorene on insulin binding to microsomal and Golgi fractions of rat liver cells. J Natl Cancer Inst 1984 0.75
90 Quantitative assessment of the development of hepatoma in a buffalo rat model. Transplant Proc 1997 0.75
91 Continuous five-day infusion of PALA and 5FU: a pilot phase II trial. Med Pediatr Oncol 1983 0.75
92 Effect of 2-acetylaminofluorene on the binding of epidermal growth factor to microsomal and Golgi fractions of rat liver cells. Cancer Res 1984 0.75
93 Antiemetic effect of intravenous diazepam in patients receiving cis-diamminedichloroplatinum II: a pilot study. Med Pediatr Oncol 1979 0.75
94 Insulin and epidermal growth factor receptors in rat liver after administration of the hepatocarcinogen 2-acetylaminofluorene: ligand binding and autophosphorylation. Cancer Res 1986 0.75
95 5-Azacytidine. Promoting activity for rat hepatocellular carcinoma. IARC Sci Publ 1984 0.75
96 Phase II trial of etoposide, vincristine, and high-dose cisplatin in advanced non-small cell lung cancer. Cancer Treat Rep 1985 0.75
97 Fine needle aspiration diagnosis of hepatocellular carcinoma in metastatic sites. Acta Cytol 1996 0.75
98 Comitogenic effects of vasoactive intestinal polypeptide on rat hepatocytes. J Cell Physiol 1996 0.75
99 Phase II trial of esorubicin in advanced pancreatic adenocarcinoma. Cancer Treat Rep 1986 0.75
100 Breast cancer with osseous metastasis and herniated lumbar disc. A cautionary tale. Cancer 1985 0.75
101 Involvement of hepatocyte epidermal growth factor receptor mediated activation of mitogen-activated protein kinase signaling pathways in response to growth inhibition by a novel K vitamin. J Cell Physiol 2000 0.75